Freestone Capital Holdings LLC bought a new stake in Actuate Therapeutics (NASDAQ:ACTU – Free Report) in the fourth quarter, HoldingsChannel reports. The fund bought 10,000 shares of the company’s stock, valued at approximately $80,000.
Separately, Sigma Planning Corp acquired a new stake in shares of Actuate Therapeutics in the fourth quarter valued at about $128,000.
Actuate Therapeutics Stock Performance
Shares of NASDAQ ACTU opened at $6.95 on Friday. Actuate Therapeutics has a fifty-two week low of $5.51 and a fifty-two week high of $11.73. The business has a 50 day moving average price of $8.25 and a two-hundred day moving average price of $8.11.
About Actuate Therapeutics
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Featured Stories
- Five stocks we like better than Actuate Therapeutics
- Why Invest in High-Yield Dividend Stocks?
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- Using the MarketBeat Dividend Tax Calculator
- 3 Stocks to Buy While Others Stay on the Sidelines
- The 3 Best Blue-Chip Stocks to Buy Now
- MarketBeat Week in Review – 03/03 – 03/07
Want to see what other hedge funds are holding ACTU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Actuate Therapeutics (NASDAQ:ACTU – Free Report).
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
